Opens in a new tab
Tuesday, 17 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

pulmonary arterial hypertension

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in pulmonary arterial hypertension

5 stories · every one Fact-Checked
Seralutinib inhaled therapy development for pulmonary arterial hypertensionHealth TidingsGossamer Bio Files First NDA for Seralutinib in Pulmonary Arterial HypertensionGossamer Bio has submitted its first New Drug Application to the FDA for inhaled seralutinib in pulmonary arterial hypertension, supported by clinical data from the Phase 3 PROSERA…25 Sep 2026 · 3 min read
Fact-Checked
WINREVAIR sotatercept HYPERION trial in newly diagnosed pulmonary arterial hypertensionHealth TidingsFDA Updates WINREVAIR Label with HYPERION Data in Newly Diagnosed PAHFDA updates the WINREVAIR label with HYPERION data showing a 76% reduction in clinical worsening risk in newly diagnosed pulmonary arterial hypertension.23 Sep 2026 · 3 min read
Fact-Checked
Ralinepag FDA NDA acceptance for pulmonary arterial hypertension treatmentHealth TidingsFDA Accepts United’s NDA for Ralinepag in Pulmonary Arterial HypertensionThe FDA has accepted United Therapeutics’ NDA for investigational ralinepag for pulmonary arterial hypertension (PAH).24 Aug 2026 · 3 min read
Fact-Checked
Illustration of pulmonary arterial hypertension treatment showing ralinepag, an investigational oral prostacyclin IP receptor agonist, reducing clinical worsening in the Phase 3 ADVANCE OUTCOMES trial published in The Lancet.Health TidingsFDA Clears Path for Gossamer’s Seralutinib NDA Submission in PAHGossamer Bio plans to submit an FDA New Drug Application for seralutinib in pulmonary arterial hypertension in September 2026 after favorable Pre-NDA meeting feedback.28 Jul 2026 · 3 min read
Fact-Checked
Illustration of IDE892, an investigational MTA-cooperative PRMT5 inhibitor, entering Phase 1/2 monotherapy expansion for MTAP-deleted pancreatic ductal adenocarcinoma and non-small cell lung cancer.Clinical TrialsInsmed Report Positive 12-Month Data from the OLE Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Pulmonary Arterial HypertensionInsmed has reported positive 12-month results from the ongoing TPIP open-label extension study in pulmonary arterial hypertension.16 Jul 2026 · 3 min read
Fact-Checked
Page 1 of 1